Overview

Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Primary Objectives - Assess ultrastructure changes in dermal myelinated nerves of patients who receive ixabepilone chemotherapy - Detailed characterization of peripheral neuropathy in patients who receive ixabepilone Secondary Objectives - Clinical benefit rate - Time to progression ( TTP) - Toxicity - Exploratory studies: - Relation of MDR 1 and TRKA polymorphisms to evolution of ultrastructural neurologic changes observed in neurons. - Relation of NGF, IL8, and IL10 to the development of clinical symptoms and ultrastructural changes in neurons.
Phase:
Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborator:
Bristol-Myers Squibb
Treatments:
Epothilones